JP6092672B2 - Orally rapidly disintegrating tablets - Google Patents
Orally rapidly disintegrating tablets Download PDFInfo
- Publication number
- JP6092672B2 JP6092672B2 JP2013057695A JP2013057695A JP6092672B2 JP 6092672 B2 JP6092672 B2 JP 6092672B2 JP 2013057695 A JP2013057695 A JP 2013057695A JP 2013057695 A JP2013057695 A JP 2013057695A JP 6092672 B2 JP6092672 B2 JP 6092672B2
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- disintegration
- rapidly disintegrating
- fragrance
- hardness
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003205 fragrance Substances 0.000 claims description 48
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 36
- 239000000843 powder Substances 0.000 claims description 31
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 28
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 14
- 238000005187 foaming Methods 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000004386 Erythritol Substances 0.000 claims description 9
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 9
- 235000019414 erythritol Nutrition 0.000 claims description 9
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 9
- 229940009714 erythritol Drugs 0.000 claims description 9
- 239000000341 volatile oil Substances 0.000 claims description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 8
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 150000005846 sugar alcohols Chemical class 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 241000207199 Citrus Species 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 235000020971 citrus fruits Nutrition 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- 239000003826 tablet Substances 0.000 description 115
- 239000000796 flavoring agent Substances 0.000 description 31
- 235000019634 flavors Nutrition 0.000 description 31
- 210000000214 mouth Anatomy 0.000 description 26
- 239000000203 mixture Substances 0.000 description 21
- 238000004519 manufacturing process Methods 0.000 description 18
- 238000002156 mixing Methods 0.000 description 18
- 239000002245 particle Substances 0.000 description 18
- 238000011156 evaluation Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 235000015165 citric acid Nutrition 0.000 description 9
- 230000003111 delayed effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000007884 disintegrant Substances 0.000 description 6
- 238000005469 granulation Methods 0.000 description 6
- 230000003179 granulation Effects 0.000 description 6
- 210000003296 saliva Anatomy 0.000 description 6
- 241000951471 Citrus junos Species 0.000 description 5
- 235000005979 Citrus limon Nutrition 0.000 description 5
- 244000131522 Citrus pyriformis Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000001055 chewing effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- -1 sucrose fatty acid ester Chemical class 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 239000004605 External Lubricant Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WLDHEUZGFKACJH-ZRUFZDNISA-K Amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1\N=N\C1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-ZRUFZDNISA-K 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000009702 powder compression Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000003232 water-soluble binding agent Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Grain Derivatives (AREA)
- General Preparation And Processing Of Foods (AREA)
- Jellies, Jams, And Syrups (AREA)
- Seasonings (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、口腔内速崩壊性錠剤に関する。 The present invention relates to an intraoral rapidly disintegrating tablet.
近年、消費者や嚥下困難な幼児、行動の不自由な患者などの服用のし易さを考慮した剤形として、水なしで服用できる錠剤の開発が望まれている。通常、錠剤などの固形製剤を服用する際には水を必要とし、利便性に欠けるという問題がある。また、大きい錠剤や、服用数量が多い錠剤は飲みにくいという問題がある。特に嚥下困難な患者や、小児、高齢者では咽喉につかえることにより、窒息することもある。一方、チュアブル錠では水を必要としないが、咀嚼力や歯が弱い小児や高齢者には適さない。これらの問題を解決する為に、口腔内で速やかに崩壊する剤形がある。 In recent years, there has been a demand for the development of tablets that can be taken without water as a dosage form that takes into account the ease of taking by consumers, infants who have difficulty swallowing, and patients with difficulty in behavior. Usually, when taking solid preparations such as tablets, water is required, and there is a problem that it is not convenient. In addition, there is a problem that it is difficult to take a large tablet or a tablet with a large dose. In particular, patients who have difficulty swallowing, children, and elderly people may suffocate by using the throat. On the other hand, chewable tablets do not require water, but are not suitable for children and elderly people with weak chewing ability and teeth. In order to solve these problems, there are dosage forms that disintegrate rapidly in the oral cavity.
速崩壊性錠剤の従来技術として、エリスリトールやマンニトールを配合した速崩壊性錠剤に関するもの(特許文献1及び特許文献2)を例示できる。特許文献1は、エリスリトールを配合することで速崩壊性を付与した圧縮組成物に関するものであり、同じく特許文献2はマンニトールを配合することで速崩壊性を付与した製剤に関するものである。このように崩壊促進剤を添加する技術が普及しているが、エリスリトールやマンニトールは成形性に乏しく、製剤化するには多くの賦形剤が必要となり、粒数が増える結果となる。
また、同じく固形医薬製剤に関する特許がある(特許文献3)。特許文献3は、医薬成分に、エリスリトール、結晶セルロース、及び崩壊剤を配合することで速崩壊性を付与しているが、使用する崩壊剤が医薬品添加物であるクロスポビドンであり、食品には使用できない。
また錠剤を多孔性にすることで速崩壊性を付与する技術(特許文献4)がある。特許文献4は、糖アルコールと澱粉を混練して浸潤塊にした後に圧延して成形し、更に減圧乾燥することで多孔性にして速崩壊性を付与した。しかしながら、製造方法が煩雑であり、特殊装置が必要であることから、汎用性にかける技術である。
また、特許文献5は、主薬成分と糖類に水を添加して湿らせ、崩壊剤としての機能を糖類にもたせ、湿潤粉体を打錠した後に乾燥することで速崩壊性を付与するものである。しかし、水と共存させることで劣化するような有効成分には用いることが難しく、更に、湿潤した錠剤を乾燥させる特殊な装置が必要であるという問題がある。
口腔内崩壊性を高めるために、口腔内で唾液と反応して発泡する成分を含有させ、速崩壊性をより強く付与させた製剤技術がある(特許文献6)。しかしこのような技術で調製された製剤は、しばしば空気中の水分と反応して、発泡が発生してしまうという問題がある。さらに、特許文献6には、アルカリ金属の炭酸塩又は重炭酸塩と繊維素グリコール酸を酸供給源とする技術が開示されている。
また速崩壊性錠剤は、口腔内で速やかに崩壊させるために製剤の表面硬度が低く設計されており、総体的にもろく、持ち運びや、包装工程で簡単に損耗してしまうという欠点が指摘されている。
このように、速崩壊性錠剤の製造に当たっては煩雑な工程や特殊な製造設備を要することなく、どのような主薬にも適用できて、かつ崩壊性に優れる一方で、容易に破損や損耗が発生しない製剤を開発することが求められている。
また、速崩壊性錠剤は口腔内で崩壊させる際に好ましい風味を与えるために香料を添加することが行われる。香味を付与するために使用する香料は、種々の香料成分が使用される。速崩壊性錠剤には、油溶性の香料を澱粉やデキストリンと各種乳化剤により調製した乳化液を噴霧乾燥した粉末香料が使用される。粉末香料の主体は精油と粉末化するための助剤としてデキストリン、澱粉類、アラビアガム、ゼラチン、カゼインなどが配合される(非特許文献1)。この粉末香料を添加すると速崩壊性錠剤の崩壊時間が遅延するとの指摘がある。
Examples of conventional techniques for rapidly disintegrating tablets include those relating to fast disintegrating tablets containing erythritol and mannitol (Patent Document 1 and Patent Document 2). Patent Document 1 relates to a compressed composition imparted with fast disintegration by blending erythritol, and Patent Document 2 relates to a preparation imparted with rapid disintegration by blending mannitol. Thus, although the technique which adds a disintegration promoter is prevailing, erythritol and mannitol have poor moldability, and many excipients are required for formulation, resulting in an increase in the number of grains.
There is also a patent relating to a solid pharmaceutical preparation (Patent Document 3). Patent document 3 gives quick disintegration by blending erythritol, crystalline cellulose, and a disintegrant into a pharmaceutical ingredient, but the disintegrant to be used is crospovidone which is a pharmaceutical additive. I can not use it.
Moreover, there exists a technique (patent document 4) which provides quick disintegration by making a tablet porous. In Patent Document 4, sugar alcohol and starch are kneaded into an infiltrated lump, then rolled and molded, and further dried under reduced pressure to make it porous and impart quick disintegration. However, since the manufacturing method is complicated and a special device is required, it is a technique for versatility.
Further, Patent Document 5 imparts quick disintegration property by adding water to the main ingredient component and saccharide to moisten, imparting the function as a disintegrant to saccharide, and compressing the wet powder, followed by drying. is there. However, it is difficult to use for an active ingredient that deteriorates when coexisting with water, and there is a problem that a special device for drying wet tablets is required.
In order to enhance the disintegration property in the oral cavity, there is a formulation technique that includes a component that reacts with saliva and foams in the oral cavity and imparts quick disintegration more strongly (Patent Document 6). However, preparations prepared by such a technique often have a problem that foaming occurs due to reaction with moisture in the air. Further, Patent Document 6 discloses a technique using an alkali metal carbonate or bicarbonate and fibrin glycolic acid as an acid supply source.
In addition, fast disintegrating tablets are designed to have a low surface hardness so that they can disintegrate quickly in the oral cavity, and they are generally fragile and have the disadvantage of being easily carried and worn out during the packaging process. Yes.
In this way, the manufacture of fast disintegrating tablets does not require complicated processes or special manufacturing equipment, and can be applied to any active ingredient and has excellent disintegration, but easily breaks and wears. There is a need to develop formulations that do not.
In addition, a fast disintegrating tablet is added with a fragrance in order to give a preferred flavor when disintegrating in the oral cavity. Various fragrance | flavor components are used for the fragrance | flavor used in order to provide a flavor. For the fast disintegrating tablet, a powder flavor obtained by spray-drying an emulsion obtained by preparing an oil-soluble flavor with starch or dextrin and various emulsifiers is used. The main component of the powdered fragrance is essential oil and an auxiliary agent for pulverization, such as dextrin, starch, gum arabic, gelatin, and casein (Non-patent Document 1). There is an indication that the disintegration time of a fast disintegrating tablet is delayed when this powder flavor is added.
好ましい香味が付与され、錠剤として必要な表面硬度を有する、速崩壊性の錠剤を提供することを課題とする。 It is an object of the present invention to provide a rapidly disintegrating tablet which has a desirable flavor and has a surface hardness required as a tablet.
本発明者らは、速崩壊性錠剤に粉末香料を添加することに起因し、発生する崩壊性を阻害する現象について検討を進めたところ、粉末香料の主成分である精油成分が原因であることが判明した。そこでさらに研究を進め、粉末香料を添加しても崩壊阻害(崩壊遅延)をきたさない錠剤とこれに用いる粉末香料を見出し、本発明を完成させた。 The present inventors have investigated the phenomenon that inhibits the disintegration that occurs due to the addition of a powdered fragrance to a fast disintegrating tablet, and it is caused by the essential oil component that is the main component of the powdered fragrance. There was found. Therefore, further research was conducted, and a tablet that does not inhibit disintegration (disintegration delay) even when a powdered fragrance was added and a powdered fragrance used for the tablet were found, and the present invention was completed.
本発明は以下の構成である。
1.賦形剤として糖類又は糖アルコールと結晶セルロースを含有し、発泡成分として多孔質炭酸カルシウム及び炭酸水素ナトリウム、酸剤としてクエン酸、および300μm以上に整粒されている粉末香料を含有する速崩壊性錠剤。
2.粉末香料中の香料成分が柑橘類の精油である1に記載の速崩壊性錠剤。
3.糖類又は糖アルコールがエリスリトールである1又は2に記載の速崩壊性錠剤。
4.クエン酸がクエン酸ナトリウムで表面を被覆された結晶クエン酸である1〜3のいずれかに記載の速崩壊性錠剤。
5.速崩壊性固形製剤の硬度が10kgf以上であることを特徴とする1〜4のいずれかに記載の速崩壊性錠剤。
6.重量が750mgの錠剤の口腔内崩壊時間が40秒以内である1〜5のいずれかに記載の速崩壊性錠剤。
7.食品である1〜6のいずれかに記載の速崩壊性錠剤。
The present invention has the following configuration.
1. Quick disintegration containing saccharides or sugar alcohol and crystalline cellulose as excipients, porous calcium carbonate and sodium bicarbonate as foaming components, citric acid as acid agent, and powdered fragrance adjusted to 300 μm or more tablet.
2. 2. The rapidly disintegrating tablet according to 1 , wherein the fragrance component in the powder fragrance is a citrus essential oil.
3. The rapidly disintegrating tablet according to 1 or 2, wherein the sugar or sugar alcohol is erythritol.
4). The rapidly disintegrating tablet according to any one of 1 to 3 , wherein the citric acid is crystalline citric acid whose surface is coated with sodium citrate.
5. The rapidly disintegrating tablet according to any one of 1 to 4 , wherein the rapidly disintegrating solid preparation has a hardness of 10 kgf or more.
6). The rapidly disintegrating tablet according to any one of 1 to 5 , wherein the tablet having a weight of 750 mg has an oral disintegration time of 40 seconds or less.
7). The rapidly disintegrating tablet according to any one of 1 to 6 , which is a food.
本発明により賦香され、摩損の少ない十分な錠剤硬度を保った錠剤でありながら、速崩壊性を有する錠剤が提供される。 According to the present invention, there is provided a tablet having a fast disintegrating property while being a tablet which is aromatized and maintains a sufficient tablet hardness with little wear.
本発明において、主賦形剤として使用する糖類とは、医薬、食品製剤の技術分野で使用されうる単糖及び二糖、並びにそれらの糖アルコールである。これらの具体的なものとしては、マンニトール、エリスリトール、キシリトール、乳糖及びグルコース、更に、マルトース、ソルビトース、トレハロース、ショ糖及び果糖などを挙げることができる。これらは単独でも2種以上組み合わせても用いることができる。特にエリスリトールは崩壊性を付与する上で好ましい。エリスリトールは錠剤に30〜50質量%、特に好ましくは40質量%を含有させることで適切な成型しやすさ、ならびに好ましい口腔内崩壊特性を錠剤にもたせることができる。 In the present invention, the saccharides used as the main excipient are monosaccharides and disaccharides that can be used in the technical fields of medicines and food preparations, and sugar alcohols thereof. Specific examples thereof include mannitol, erythritol, xylitol, lactose and glucose, as well as maltose, sorbitol, trehalose, sucrose and fructose. These may be used alone or in combination of two or more. In particular, erythritol is preferable for imparting disintegration properties. When erythritol is contained in the tablet in an amount of 30 to 50% by mass, particularly preferably 40% by mass, the tablet can have appropriate ease of molding and preferable oral disintegration characteristics.
一般に、錠剤硬度を高めるには、水溶性結合剤として、例えば、ポリビニルピロリドン、ヒドロキシプロピルメチルセルロース、メチルセルロース、ポリビニルアルコールなどが使用されているが、通常の圧縮成形過程で得られる錠剤は速やかな崩壊性を示さない。本発明では、このような結合剤を使用せずに、結晶セルロースと崩壊剤として加工デンプンを適量添加するため、造粒工程を必要としない簡便な直接打錠法により、適度な硬度を有しかつ口腔内で速やかに崩壊する特徴をもつ錠剤を成型することができる。結晶セルロースは錠剤中に10〜20質量%を配合する。加工デンプンは同じく錠剤中に2〜5%含有させることで好ましい結果を得ることができる。 In general, in order to increase tablet hardness, for example, polyvinylpyrrolidone, hydroxypropylmethylcellulose, methylcellulose, polyvinyl alcohol and the like are used as water-soluble binders. However, tablets obtained in a normal compression molding process are rapidly disintegrating. Not shown. In the present invention, since a suitable amount of modified cellulose is added as crystalline cellulose and a disintegrant without using such a binder, it has an appropriate hardness by a simple direct tableting method that does not require a granulation step. And a tablet with the characteristic of disintegrating rapidly in an oral cavity can be shape | molded. Crystalline cellulose is blended in an amount of 10 to 20% by mass in the tablet. A preferable result can be obtained by containing 2 to 5% of the modified starch in the tablet.
本発明の主たる特徴の一つは、酸源と1種類又は複数の発泡源を唾液中の水分を介して反応させて糖類及び崩壊剤を含有する製剤の崩壊を促進させることにある。酸源としてクエン酸、発泡源としてアルカリ金属、アルカリ土類金属の炭酸塩及び重炭酸塩よりなる群から選ばれる少なくとも1種とを配合し、必要に応じて矯味あるいは微発泡の補助として1錠中に少量の他の有機酸を配合することができる。
特に発泡源としては重炭酸ナトリウムと炭酸カルシウムの併用が好ましい。本発明においては、炭酸カルシウムは多孔性炭酸カルシウム又は多孔質炭酸カルシウムが特に好ましい。
One of the main characteristics of the present invention is to promote the disintegration of a preparation containing a saccharide and a disintegrant by reacting an acid source with one or more foaming sources via water in saliva. Citric acid as the acid source, at least one selected from the group consisting of carbonates and bicarbonates of alkali metals, alkaline earth metals as the foaming source, and 1 tablet as an adjunct to taste masking or fine foaming as necessary Small amounts of other organic acids can be incorporated therein.
In particular, the combined use of sodium bicarbonate and calcium carbonate is preferred as the foaming source. In the present invention, the calcium carbonate is particularly preferably porous calcium carbonate or porous calcium carbonate.
本発明に用いる多孔質炭酸カルシウムは、化学合成された高純度軽質炭酸カルシウムであり、微粒子が連なった連鎖状粒子を多段階炭酸化することにより得られるポーラスな炭酸カルシウムで、例えば、ポアカル−N(白石カルシウム社製)、IK−3000(白石中央研究所社製)として入手できる。この多孔質炭酸カルシウムと重炭酸ナトリウムを等量併用することが、本発明における発泡源として好ましい態様である。本発明における、多孔質炭酸カルシウムの配合量は、0.5〜1.5重量%であり、0.8〜1.0重量%が特に好ましい。配合量が少ないと、崩壊を促進できず、配合量が多いと、口腔内で発泡がはげしいため、かえって摂取しにくくなり、結果的に崩壊も遅延する。
重炭酸ナトリウムはクエン酸と速やかに反応して発泡し、炭酸カルシウムはこれに遅れて発泡を開始する、このように両者を併用することで発泡時間を延長し、発泡感を感じさせず崩壊を促進させることが可能となる。重炭酸ナトリウムの配合量は、0.5〜1.5重量%であり、0.8〜1.0重量%が特に好ましい。配合量が少ないと、崩壊を促進できず、配合量が多いと、口腔内で発泡がはげしいため、かえって摂取しにくくなり、結果的に崩壊も遅延する。
重炭酸ナトリウムと多孔質炭酸ナトリウムを併用する場合は両者を等量とし、錠剤あたり1質量%以上とすることで好ましい結果を得ることができる。
The porous calcium carbonate used in the present invention is a chemically synthesized high-purity light calcium carbonate, and is porous calcium carbonate obtained by multi-stage carbonation of chain-like particles in which fine particles are connected. For example, Porecal-N (Manufactured by Shiraishi Calcium Co., Ltd.) and IK-3000 (manufactured by Shiroishi Central Research Laboratories) It is a preferred embodiment as a foaming source in the present invention to use an equal amount of porous calcium carbonate and sodium bicarbonate. The compounding quantity of the porous calcium carbonate in this invention is 0.5 to 1.5 weight%, and 0.8 to 1.0 weight% is especially preferable. If the blending amount is small, disintegration cannot be promoted. If the blending amount is large, foaming is severe in the oral cavity, making it difficult to ingest, and as a result, disintegration is delayed.
Sodium bicarbonate reacts quickly with citric acid and foams, and calcium carbonate starts foaming later. In this way, the combined use of both increases the foaming time and prevents the foaming feeling from collapsing. It becomes possible to promote. The blending amount of sodium bicarbonate is 0.5 to 1.5% by weight, particularly preferably 0.8 to 1.0% by weight. If the blending amount is small, disintegration cannot be promoted. If the blending amount is large, foaming is severe in the oral cavity, making it difficult to ingest, and as a result, disintegration is delayed.
When sodium bicarbonate and porous sodium carbonate are used in combination, a preferable result can be obtained by setting both to the same amount and 1% by mass or more per tablet.
クエン酸は唾液に溶解することで、多孔質炭酸カルシウム及び重炭酸ナトリウムと反応して発泡させて錠剤を内部からの力で崩壊させてゆく。しかしクエン酸は空気中の水分を介して徐々に発泡剤と反応する。これを抑制するため、クエン酸顆粒の表面をクエン酸ナトリウムで被覆した原料を使用すると、このような経時的な変化を抑制できる。このようなクエン酸ナトリウムでクエン酸顆粒の表面を被覆したものとしてCCA(三栄源FFI社製)を例示することができる。クエン酸の配合量は、0.5〜1.5重量%であり、0.8〜1.0重量%が特に好ましい。配合量が少ないと、崩壊を促進できず、配合量が多いと、口腔内で感じる酸味が強すぎるため、かえって摂取しにくくなる。 When citric acid dissolves in saliva, it reacts with porous calcium carbonate and sodium bicarbonate to cause foaming and disintegrate the tablet with the force from the inside. However, citric acid gradually reacts with the blowing agent via moisture in the air. In order to suppress this, when a raw material in which the surface of citrate granules is coated with sodium citrate is used, such a change with time can be suppressed. CCA (manufactured by San-Ei Gen FFI Co., Ltd.) can be exemplified as the citrate granule coated with such sodium citrate. The amount of citric acid is 0.5 to 1.5% by weight, particularly preferably 0.8 to 1.0% by weight. If the blending amount is small, disintegration cannot be promoted, and if the blending amount is large, the sourness felt in the oral cavity is too strong, which makes it difficult to ingest.
本発明の錠剤は、口腔内での崩壊の際に好ましい香味を付与するために、粉末香料を配合する。粉末香料は香味成分として精油を含有し、デキストリン、澱粉類、アラビアガム、ゼラチン、カゼインなどを含有し、粉末化されたものであって、粉末香料の粒子径を300μm以上に整粒されたものを用いなければならない。この粒子径よりも小さな粒子径の粉末香料が混入する場合は、速崩壊性を阻害する。特に精油を香料成分として含有する粉末香料を使用する場合は注意を要する。
このような粉末香料は、市販されている粉末香料を篩別して得ることができる。
また粉末香料を調製する工程において、造粒操作を行い、粒子径を300μm以上になるように造粒しても良い。造粒は噴霧乾燥法によって粉末香料を調製した後、湿式造粒や乾式造粒など公知の技術に基づき調製することができる。
The tablet of this invention mix | blends a powder fragrance | flavor in order to provide a preferable flavor in the case of disintegration in an oral cavity. Powdered fragrance contains essential oil as a flavor component and contains dextrin, starch, gum arabic, gelatin, casein, etc., and is pulverized, and the particle size of the powdered fragrance is sized to 300 μm or more Must be used. When the powdered fragrance | flavor with a particle diameter smaller than this particle diameter mixes, fast disintegration is inhibited. In particular, care is required when using a powdered fragrance containing an essential oil as a fragrance component.
Such a powder flavor can be obtained by sieving a commercially available powder flavor.
Further, in the step of preparing the powdered fragrance, granulation may be performed so that the particle diameter is 300 μm or more. Granulation can be prepared based on a known technique such as wet granulation or dry granulation after powder fragrance is prepared by spray drying.
本発明の錠剤は、上記以外の材料として、打錠に必要な滑沢剤や流動化剤を配合することができる。また口腔内での唾液の分泌を促進させる成分を配合することで、より速やかな口腔内崩壊をもたらすことができる。このような唾液分泌促進剤として、ポリグルタミン酸を例示することができる。 The tablet of this invention can mix | blend the lubricant and fluidizing agent required for tableting as materials other than the above. Further, by incorporating a component that promotes the secretion of saliva in the oral cavity, more rapid oral disintegration can be brought about. An example of such a saliva secretion promoter is polyglutamic acid.
本発明において適用可能な薬効成分(主薬)は、経口で摂取できるいかなる医薬成分、あるいは栄養成分、機能成分も含むことができ、水溶性のみならず難水溶性薬効成分も使用することができる。更に、苦味のないか少ないものが好ましいが、苦味を有するものでもコーティング処理を行うなどして使用できる。これらの主薬成分は、1種または2種以上を組み合わせて含むことができる。主薬成分は、糖類と崩壊剤、発泡剤の混合物の混合工程で調製される打錠用末中に添加することができる。また必要に応じて造粒を行った後、打錠することもできる。主薬の配合量は錠剤あたり50質量%以下とすることが好ましい。これ以上の含有量とする場合には打錠において、キャッピングなどの問題が発生する場合がある。 The medicinal component (main drug) applicable in the present invention can include any medicinal component that can be taken orally, or a nutritional component and a functional component. Not only water-soluble but also poorly water-soluble medicinal components can be used. In addition, those having little or no bitterness are preferred, but those having bitterness can also be used after coating. These main ingredient components can be used alone or in combination of two or more. The main drug component can be added to the tableting powder prepared in the mixing step of a mixture of sugar, disintegrant and foaming agent. Moreover, after granulating as needed, it can also be tableted. The blending amount of the active ingredient is preferably 50% by mass or less per tablet. When the content is more than this, problems such as capping may occur in tableting.
打錠用末は、本発明の効果に悪影響を及ぼさない限り、錠剤の製造に一般に用いられる種々の添加剤を含むことができる。結合剤以外の添加剤としては、例えば、クエン酸、酒石酸、リンゴ酸などの酸味料、例えば、アスパルテーム、サッカリンナトリウム、ステビアなどの人工甘味料、例えば、ステアリン酸マグネシウム、ショ糖脂肪酸エステル、タルクなどの滑沢剤、例えば、食用黄色5号、食用赤色2号及び食用青色2号などの食用色素、食用レーキ色素、酸化鉄などの着色剤を挙げることができる。これらの添加剤は、1種または2種以上を組み合わせて使用することができる。 The powder for tableting may contain various additives generally used for tablet production as long as the effects of the present invention are not adversely affected. Examples of additives other than the binder include acidulants such as citric acid, tartaric acid and malic acid, artificial sweeteners such as aspartame, sodium saccharin and stevia, such as magnesium stearate, sucrose fatty acid ester and talc. Lubricants, for example, edible dyes such as edible yellow No. 5, edible red No. 2 and edible blue No. 2, edible lake dyes, and coloring agents such as iron oxide can be mentioned. These additives can be used alone or in combination of two or more.
本発明の製造工程の一例を図1に示す。本発明の製造方法はこの工程に限定されるものではない。また滑沢剤は組成中に添加するのではなく、外部滑沢剤として使用しても良い。
本発明の構成は、簡単な混合と打錠による極めて簡便な方法で、目的とする香味を付与された速崩壊性の錠剤を製造できる優れたものである。打錠工程では、一般に粉末の圧縮成形に常用されている打錠機、例えば、単発打錠機或いはロータリー式打錠機を使用することができる。打錠圧は、例えば、打錠用末200mgを、直径(φ)8mmの杵及び単発打錠機を用いて打錠する場合、通常、200〜1500kg、好ましくは500〜1000kg程度に設定する。打錠時の温度は、通常室温(20〜30℃程度)でよく、特に調整する必要はない。本発明の口腔内速崩壊性錠剤は適度な硬度を有しているため、円形、楕円形などの所望される形状に加工することができる。このような錠剤の直径或いは長径は、通常6〜15mmであり、その重量は、通常、80mgから1000mgとなるが、これに限定されるものではない。また、錠剤に分割するための割線を刻んだ分割錠とすることも可能である。
本発明による錠剤は口腔内での速崩壊性を備えながら、直径15mmの錠剤硬度が10kgfを超えており、製造・流通・保管に耐え得る錠剤硬度を有している。
An example of the production process of the present invention is shown in FIG. The production method of the present invention is not limited to this step. Further, the lubricant may not be added during the composition but may be used as an external lubricant.
The constitution of the present invention is excellent in that a rapidly disintegrating tablet imparted with the desired flavor can be produced by a very simple method by simple mixing and tableting. In the tableting process, a tableting machine commonly used for powder compression molding, for example, a single tableting machine or a rotary tableting machine can be used. The tableting pressure is usually set to about 200 to 1500 kg, preferably about 500 to 1000 kg, when, for example, 200 mg of tableting powder is tableted using a punch with a diameter (φ) of 8 mm and a single tableting machine. The temperature at the time of tableting may be usually room temperature (about 20 to 30 ° C.), and it is not necessary to adjust in particular. Since the intraoral rapidly disintegrating tablet of the present invention has an appropriate hardness, it can be processed into a desired shape such as a circle or an ellipse. The diameter or major axis of such a tablet is usually 6 to 15 mm, and its weight is usually 80 mg to 1000 mg, but is not limited thereto. Moreover, it is also possible to set it as the split tablet which engraved the dividing line for dividing | segmenting into a tablet.
The tablet according to the present invention has a tablet hardness of 10 mmf with a diameter of 15 mm while having rapid disintegration property in the oral cavity, and has a tablet hardness that can withstand manufacturing, distribution, and storage.
本発明の口腔内速崩壊性錠剤は、口腔内での速やかな崩壊性を有しているため、飲み易くかつ取り扱いが容易である。また賦香することにより小児などに飲用しやすくなるとともに、市販の粉末香料を配合した場合の崩壊性の阻害も発生しない。
したがって、含有する薬効成分に応じて適用される患者、特に高齢者への長期投与の服用に適しており、また、薬剤の異味や異臭が香料によってマスキングできるため小児患者の予防や治療にも用いることができる。さらに唾液量の少ないシェーグレン症候の患者や老人などに服用させる場合には、最小限の水で速やかに崩壊するため利便である。また、水摂取の制限されている患者や小児にも適している。
Since the rapidly disintegrating tablet in the oral cavity of the present invention has rapid disintegrating property in the oral cavity, it is easy to drink and easy to handle. Moreover, it becomes easy to drink for children etc. by perfume, and the disintegration inhibition at the time of mix | blending a commercially available powdered fragrance | flavor does not generate | occur | produce.
Therefore, it is suitable for long-term administration to patients applied according to the medicinal properties contained, especially for elderly people, and it can also be used for prevention and treatment of pediatric patients because the taste and odor of drugs can be masked by perfumes. be able to. Furthermore, when taking it to a patient with Sjögren's syndrome or an elderly person with a small amount of saliva, it is convenient because it quickly disintegrates with a minimum amount of water. It is also suitable for patients and children with limited water intake.
本発明の製造方法によれば、汎用の粉砕機、混合機、打錠機を使用できるため従来の製造装置がそのまま利用できる。更に、薬効成分の溶解特性により製造工程を変更または追加する必要もない。したがって、本発明の製造方法は、煩雑な工程を経ることなく製造工程が極めて簡便であり、製造コスト、製造時間などの面から、従来の口腔内速崩壊性錠剤の製造方法に比較して有利である。また、医薬品だけでなく健康食品や錠菓としても有用な製品となる。 According to the production method of the present invention, since a general-purpose pulverizer, mixer and tablet press can be used, the conventional production apparatus can be used as it is. Furthermore, there is no need to change or add to the manufacturing process depending on the dissolution characteristics of the medicinal ingredients. Therefore, the production method of the present invention is extremely simple without involving complicated steps, and is advantageous from the viewpoint of production cost, production time, and the like, compared to the conventional method for producing an orally rapidly disintegrating tablet. It is. Moreover, it becomes a useful product not only as a medicine but also as a health food and tablet confectionery.
以下に、参考例、試験例を示し、本発明について更に詳細に説明をする。 Reference examples and test examples are shown below, and the present invention will be described in more detail.
参考例
香料無添加の速崩壊性錠剤の製造
1.錠剤の製造
表1の組成で速崩壊性錠剤を調製した。なお、主薬にはN-アセチルグルコサミン(焼津水産化学社製)、多孔質炭酸カルシウムはポアカル−N(白石カルシウム社製)を用いた。
Reference example
Production of fast disintegrating tablets without flavoring Manufacture of tablets Quick disintegrating tablets were prepared with the composition shown in Table 1. In addition, N-acetylglucosamine (manufactured by Yaizu Suisan Chemical Co., Ltd.) was used as the main agent, and Porecal-N (manufactured by Shiraishi Calcium Co., Ltd.) was used as the porous calcium carbonate.
図1の手順で、一次混合を10分間、二次混合を5分間、V型混合機(筒井理化学社製 ミクロ形V形混合機 S-3形)を用いて行い、ついで単発打錠機(岡田精工社製 N-30E)を用いて、錠剤の硬度が10kgf以上になるよう打錠圧を設定(約1000kgf前後)し、直径15mm、厚さ3.5mm、重量750mgの錠剤を製造した。 In the procedure shown in Fig. 1, primary mixing is performed for 10 minutes and secondary mixing is performed for 5 minutes using a V-type mixer (Micro-type V-type mixer S-3, manufactured by Tsutsui Richemical Co., Ltd.). N-30E) manufactured by Okada Seiko Co., Ltd. was used to set the tableting pressure (about 1000 kgf) so that the tablet hardness was 10 kgf or more, and tablets with a diameter of 15 mm, a thickness of 3.5 mm, and a weight of 750 mg were produced.
2.錠剤の評価
(1)硬度
硬度は木屋式硬度計にて測定した。なお、本錠剤が製造、流通、保管に耐え得る硬度として、今回は少なくとも9kgf以上、より好ましくは10kfg以上の硬度を有していることを評価条件とした。なお、本錠剤の場合、絶対硬度で表すならば、0.17kgf/mm2以上、より好ましくは0.19kgf/mm2以上の硬度を有していることを評価条件とする。
なお、絶対硬度は以下の式にて算出される。
絶対硬度(kgf/mm2)=錠剤硬度(破壊強度,kgf)/錠剤の断面積(mm2)
で表し、錠剤の断面積は、今回のような平錠である場合、
錠剤の断面積(mm2)=錠剤直径(mm)×錠剤厚み(mm)
で算出される。
2. Evaluation of tablet (1) Hardness The hardness was measured with a Kiyama hardness tester. It should be noted that, as the hardness that the tablet can withstand manufacture, distribution, and storage, this time, the evaluation condition was that it had a hardness of at least 9 kgf or more, more preferably 10 kfg or more. In the case of this tablet, when expressed in absolute hardness, the evaluation condition is that the tablet has a hardness of 0.17 kgf / mm 2 or more, more preferably 0.19 kgf / mm 2 or more.
The absolute hardness is calculated by the following formula.
Absolute hardness (kgf / mm 2 ) = Tablet hardness (breaking strength, kgf) / Table cross-sectional area (mm 2 )
The cross-sectional area of the tablet is a flat tablet like this time,
Tablet cross-sectional area (mm 2 ) = tablet diameter (mm) x tablet thickness (mm)
Is calculated by
(2)摩損度
第14薬局方参考情報の仕様で製作された錠剤摩損度試験機を用いて、錠剤の摩損度を測定した。通常の市販製剤である本願発明品と同径のチュアブル錠(ファンケル社製)の摩損度である3%以下を基準として評価した。
(2) Friction degree The friability of the tablet was measured using a tablet friability tester manufactured according to the specifications of the 14th Pharmacopoeia reference information. Evaluation was based on 3% or less, which is the friability of chewable tablets (manufactured by FANCL) having the same diameter as the present invention product, which is a normal commercial preparation.
(3)崩壊状況の観察(シャーレ試験法)
シャーレの上に10gの試験液(水にビタミンB12を添加して赤く着色したもの)を入れ、その上にキムワイプを一枚、四つ折りにして浸す。浸したキムワイプの上に錠剤を軽く押し付けるように置き、置いてから錠剤上部まで全てに試験液が浸透するまでの時間を測定する。錠剤は底面のみでキムワイプに接し、試験液はキムワイプを通じてのみ錠剤に移行する。錠剤上部まで赤色が移行したときを崩壊時間とし、その時点の製剤の崩壊状況を観察した。また製剤の上面及び側面の崩壊状況を写真撮影した。
(3) Observation of disintegration situation (petri dish test method)
Put 10g of the test solution (colored red by adding vitamin B12 to water) on the petri dish, and immerse the Kimwipe in one fold. Place the tablet lightly on the soaked Kimwipe and measure the time from placement until the test solution penetrates all the way to the top of the tablet. The tablet touches the Kimwipe only at the bottom, and the test solution is transferred to the tablet only through the Kimwipe. The time when the red color was transferred to the top of the tablet was taken as the disintegration time, and the disintegration state of the preparation at that time was observed. In addition, photographs were taken of the disintegration of the top and side surfaces of the preparation.
(4)口腔内崩壊時間の測定と官能評価(官能試験法)
5名の健常な成人からなるパネルによって評価した。
サンプル錠剤を口腔内で噛まずに舌で転がしながら溶かし、固形物が無くなるまでの時間を測定した。
また服用感の評価を行った。
口腔内崩壊時間は5名の平均時間を口腔内崩壊時間とした。
服用感は5名の協議により、次の基準で口腔内での状況を勘案して評価した。また各錠剤の欠点を適切な評語で表すこととした。
×:食感が不快で許容外
△:食感が不快ではあるが許容
○:食感が良好
◎:食感が非常に良い
(4) Oral disintegration time measurement and sensory evaluation (sensory test method)
Evaluation was made by a panel of 5 healthy adults.
The sample tablet was melted while rolling with the tongue without chewing in the mouth, and the time until the solid matter disappeared was measured.
Moreover, the feeling of administration was evaluated.
Oral disintegration time was defined as the average disintegration time of 5 persons.
The feeling of ingestion was evaluated in consideration of the situation in the oral cavity according to the following criteria based on the discussion of five people. In addition, the defect of each tablet was expressed by an appropriate word.
×: Texture is unpleasant and not acceptable △: Texture is uncomfortable but acceptable ○: Texture is good ◎: Texture is very good
(5)保存安定性試験
40℃湿度75%の環境下で7日保存し、同時に5℃でアルミ袋密封したものも保存し、両者を対比して形状、色変化を肉眼で観察し、次の評価基準で保存安定性を評価した。
×:差が歴然で製品として成立しない
△:品質が損なわれ差が認識できる
○:差がほとんど認識されない
(5) Storage stability test
Store for 7 days in an environment of 40 ° C and 75% humidity, and at the same time store an aluminum bag sealed at 5 ° C. Compare the two and observe the shape and color with the naked eye. Storage stability according to the following evaluation criteria Evaluated.
×: Difference is obvious and product is not established △: Quality is impaired and difference can be recognized ○: Difference is hardly recognized
3.錠剤の評価結果
評価結果を表2に示す。また各錠剤の崩壊状況を観察した画像を図2に示す。
3. Table 2 shows the evaluation results of the tablets. Moreover, the image which observed the disintegration condition of each tablet is shown in FIG.
以上の評価のとおり、参考例1,2の錠剤は水の浸透が早く、口腔内で完全に溶解し、口腔内に異物感を残さなかった。また、速崩壊性錠剤としての硬度を超える錠剤硬度を持ち、錠剤として必要かつ充分な摩損度のレベルを超える高水準であった。
しかし参考例2の処方に、市販されている各種の柑橘類の粉末香料を1〜2%添加して賦香した錠剤を製造したところ、上記のシャーレを用いた崩壊時間および口腔内崩壊時間のいずれもが2分30秒以上に遅延し、速崩壊性が失われることが判明した。崩壊性の遅延の原因を確認するため以下の試験を行った。
As described above, the tablets of Reference Examples 1 and 2 were rapidly penetrated by water, completely dissolved in the oral cavity, and did not leave a foreign body sensation in the oral cavity. Moreover, it had a tablet hardness exceeding the hardness as a fast disintegrating tablet, and was a high level exceeding the level of friability necessary and sufficient as a tablet.
However, when the tablets prepared by adding 1-2% of various commercially available citrus powder fragrances to the formulation of Reference Example 2 to produce a fragrance, either the disintegration time using the petri dish or the disintegration time in the oral cavity was obtained. Was delayed for 2 minutes 30 seconds or more, and it was found that the rapid disintegration was lost. The following tests were conducted to confirm the cause of the disintegrating delay.
試験例1
参考例2の錠剤の組成を基本組成として、さらに粉末香料の構成成分を添加した場合の崩壊性遅延を試験した。なお配合の一部を本試験の目的に合わせて変更している。
市販の柑橘類粉末香料として次の表3、表4の組成の香料を用いて、参考例2と同様に、表5の組成の錠剤を調製した。香料はレモンフレーバーパウダーNo.40604(コーケン香料社製)、ゆずC72(ゆずフレーバーパウダー:佐藤食品工業社製)の2種類である。
得られた2種の錠剤および参考例2の各錠剤をシャーレ試験法によって崩壊試験を行った。シャーレ試験の崩壊時間を表6に示した。
Test example 1
Using the composition of the tablet of Reference Example 2 as a basic composition, the disintegration delay when a constituent of a powdered fragrance was added was tested. Part of the formulation has been changed to suit the purpose of this test.
Tablets having the composition shown in Table 5 were prepared in the same manner as in Reference Example 2, using the fragrances having the compositions shown in Tables 3 and 4 as commercially available citrus powder fragrances. The fragrance is lemon flavor powder no. There are two types, 40604 (manufactured by Koken Inc.) and Yuzu C72 (Yuzu flavor powder: manufactured by Sato Foods Co., Ltd.).
The disintegration test was performed on the obtained two kinds of tablets and each tablet of Reference Example 2 by a petri dish test method. Table 6 shows the disintegration time of the petri dish test.
レモンフレーバーパウダー、ゆずフレーバーパウダーのいずれも崩壊を大幅に遅延させることが確認された。また両方の香料の共通成分であるデキストリンおよび、レモンフレーバーパウダーに添加されているアラビアガムは、別途実施した試験で崩壊を遅延させないことを確認した。
表6の試験結果および他の配合成分の崩壊性に及ぼす影響から、表3、表4の2種類の粉末香料の共通成分である精油が崩壊性を遅延させることが予想された。
It was confirmed that both the lemon flavor powder and the yuzu flavor powder significantly delayed the disintegration. It was also confirmed that dextrin, which is a common component of both fragrances, and gum arabic added to lemon flavor powder did not delay disintegration in a separately conducted test.
From the test results in Table 6 and the effects of other blending components on the disintegration properties, it was predicted that the essential oil, which is a common component of the two types of powder flavors in Tables 3 and 4, delayed the disintegration properties.
試験例1の結果から精油成分の配合が速崩壊性を阻害し、崩壊を遅延させることが予想された。これは粉末香料の配合が、参考例2の処方においては、速崩壊性錠剤とすることが困難であることが予想された。
そこで、本発明者は、粉末香料を用いた予備試験を実施したところ、粉末香料の粒子径を揃えることで抑制できる可能性を見出した。
そこで、粉末香料の粒子径を整え、最適な粒子径を確認する試験を行った。
From the results of Test Example 1, it was predicted that the blending of essential oil components inhibited the rapid disintegration property and delayed disintegration. It was expected that it was difficult for the powdered fragrance to be a rapidly disintegrating tablet in the formulation of Reference Example 2.
Then, when this inventor implemented the preliminary test using a powder fragrance | flavor, he found possibility that it could suppress by equalizing the particle diameter of a powder fragrance | flavor.
Therefore, a test for adjusting the particle size of the powdered fragrance and confirming the optimum particle size was conducted.
試験例2
崩壊速度に対する粉末香料の粒子径の影響を確認した。
1.粉末香料の粒子径の均一化
表3、表4の市販レモンフレーバーパウダー、ゆずフレーバーパウダーを用いて粒子径の均一な粉末化香料を調製し、本試験に用いた。
フードミル1000(TESCOM社製)を使用し攪拌造粒を行った。バインダーとして70%エタノールを使用し、エタノール添加のつど30秒程度の攪拌を繰り返し造粒した。最終的に粉末香料の重量の約10%程度の70%エタノールを数回に分けて滴下した。
造粒後得られた顆粒をJIS規格16メッシュの篩で整粒した。篩通過顆粒のみを乾燥器DRU600TA(ADVANTEC社製)に入れ、37℃で一晩乾燥させた。
乾燥後、メッシュサイズ32、48、100、200の篩を使用して篩い分けし、得られた顆粒を篩の目のサイズに基づき、粒径ごとに、75μm以下、75〜150μm、150〜300μm、300〜500μm、500μm以上の5段階のサイズに均一化した粉末香料を得た。
Test example 2
The influence of the particle size of the powdered fragrance on the disintegration rate was confirmed.
1. Uniformization of particle diameter of powdered fragrances Powdered fragrances with uniform particle diameters were prepared using the commercially available lemon flavor powders and yuzu flavored powders shown in Tables 3 and 4 and used in this test.
Agitation granulation was performed using a food mill 1000 (manufactured by TESCOM). 70% ethanol was used as a binder, and granulation was repeated for about 30 seconds each time ethanol was added. Finally, 70% ethanol, which is about 10% of the weight of the powdered fragrance, was dropped in several portions.
Granules obtained after granulation were sized with a JIS standard 16 mesh sieve. Only the granules passed through the sieve were placed in a dryer DRU600TA (ADVANTEC) and dried overnight at 37 ° C.
After drying, it is sieved using a sieve of mesh size 32, 48, 100, 200, and the resulting granules are 75 μm or less, 75 to 150 μm, 150 to 300 μm for each particle size based on the size of the sieve mesh , 300 to 500 μm, and a powdered fragrance homogenized in five stages of 500 μm or more were obtained.
2.速崩壊性錠剤の調製
表5の組成になるよう各成分および造粒した粉末香料を秤量し、ついで、30メッシュの篩を用いて再度篩過し、ミクロ形V形混合機 S-3形(筒井理化学社製)を用いて10分間混合した。なお造粒した、粉末香料は、表3、表4に示すレモンフレーバーパウダー、ゆずフレーバーパウダーを造粒して用いた。
次いでφ15の平杵を設置した単発打錠機N-30E(岡田精工社製)を使用して打錠を行い、重量750mgの錠剤を得た。なおスティッキングを防ぐためにステアリン酸カルシウムを外部滑沢剤として用いた。打錠圧は、錠剤硬度10kgf(木屋式硬度計にて測定)以上になるように設定して打錠を行った。評価結果を表7、表8に示した。
2. Preparation of fast disintegrating tablet Weigh each ingredient and granulated powdered fragrance so as to have the composition shown in Table 5, then sieve again using a 30-mesh sieve, and form a micro V-shaped mixer S-3 ( And mixed for 10 minutes. The granulated powder flavor was granulated from lemon flavor powder and yuzu flavor powder shown in Tables 3 and 4.
Next, tableting was performed using a single tableting machine N-30E (manufactured by Okada Seiko Co., Ltd.) equipped with a φ15 flat punch to obtain a tablet having a weight of 750 mg. In order to prevent sticking, calcium stearate was used as an external lubricant. Tableting pressure was set at a tablet hardness of 10 kgf (measured with a Kiyama hardness tester) or more. The evaluation results are shown in Tables 7 and 8.
3.評価
調製した各錠剤について、以下の方法で評価した。
(1)硬度
硬度は木屋式デジタル硬度計により、錠剤径の方向に圧縮して測定した。なお、本錠剤が製造、流通、保管に耐え得る硬度として、今回は少なくとも9kgf以上、より好ましくは10kgf以上の硬度を有していることを評価条件とした。なお、本錠剤の場合、絶対硬度で表すならば、0.17kgf/mm2以上、より好ましくは0.19kgf/mm2以上の硬度を有していることを評価条件とする。
なお、絶対硬度は以下の式にて算出される。
絶対硬度(kgf/mm2)=錠剤硬度(破壊強度,kgf)/錠剤の断面積(mm2)
で表し、錠剤の断面積は、今回のような平錠である場合、
錠剤の断面積(mm2)=錠剤直径(mm)×錠剤厚み(mm)
3. Evaluation Each prepared tablet was evaluated by the following method.
(1) Hardness Hardness was measured by compressing in the tablet diameter direction with a Kiyama digital hardness meter. The evaluation condition was that the tablet has a hardness that can withstand the manufacture, distribution, and storage, at least 9 kgf or more, more preferably 10 kgf or more this time. In the case of this tablet, when expressed in absolute hardness, the evaluation condition is that the tablet has a hardness of 0.17 kgf / mm 2 or more, more preferably 0.19 kgf / mm 2 or more.
The absolute hardness is calculated by the following formula.
Absolute hardness (kgf / mm 2 ) = Tablet hardness (breaking strength, kgf) / Table cross-sectional area (mm 2 )
The cross-sectional area of the tablet is a flat tablet like this time,
Tablet cross-sectional area (mm 2 ) = tablet diameter (mm) x tablet thickness (mm)
(2)摩損度
第14薬局方参考情報の仕様で製作された錠剤摩損度試験機を用いて、錠剤の摩損度を測定した。
(2) Friction degree The friability of the tablet was measured using a tablet friability tester manufactured according to the specifications of the 14th Pharmacopoeia reference information.
(3)口腔内崩壊時間の測定と官能評価(官能試験法)
5名の健常な成人からなるパネルによって評価した。
サンプル錠剤を口腔内で噛まずに舌で転がしながら溶かし、固形物が無くなるまでの時間を測定した。
また服用感の評価を行った。
口腔内崩壊時間は5名の平均時間を口腔内崩壊時間とした。
服用感は5名の協議により、次の基準で口腔内での状況を勘案して評価した。また各製剤の欠点を適切な評語で表すこととした。
×:食感が不快で許容外
△:食感が不快ではあるが許容
○:食感が良好
◎:食感が非常に良い
(3) Measurement of oral disintegration time and sensory evaluation (sensory test method)
Evaluation was made by a panel of 5 healthy adults.
The sample tablet was melted while rolling with the tongue without chewing in the mouth, and the time until the solid matter disappeared was measured.
Moreover, the feeling of administration was evaluated.
Oral disintegration time was defined as the average disintegration time of 5 persons.
The feeling of ingestion was evaluated in consideration of the situation in the oral cavity according to the following criteria based on the discussion of five people. Moreover, it was decided to express the defects of each preparation with appropriate reviews.
×: Texture is unpleasant and not acceptable △: Texture is uncomfortable but acceptable ○: Texture is good ◎: Texture is very good
(4)評価結果
錠剤の硬度は、いずれも10kgf以上の測定値を示した。摩損度はいずれも3%以下であった。
口腔内崩壊時間および口腔内官能試験の評価結果を表7、表8、図3に示す。
(4) Evaluation results The hardness of the tablets showed measured values of 10 kgf or more. The degree of friability was 3% or less in all cases.
The evaluation results of the oral disintegration time and the oral sensory test are shown in Table 7, Table 8, and FIG.
表7、図3に示すとおり、全ての錠剤が1分以内の崩壊時間であり、粉末香料を造粒し、整粒することで口腔内崩壊時間は劇的に短縮された。また粉末香料の粒子径を300μm以上にすることで口腔内崩壊時間を40秒以内に短縮することができた。さらに粉末香料の粒子径を500μm以上にすると口腔内崩壊時間を30秒ほどに短縮できた。また口腔内の食感は粒子径500μmにすることで食感の不快感がなくなり、好ましい評価となった。
以上の試験結果から、粉末香料に含まれる精油による崩壊遅延を抑制するためには、粉末香料の粒子径を300μm以上に整粒すれば良く、500μm以上に整粒すると官能面でさらに良くなることが明らかとなった。
またこのような粉末香料を用いて調製した製剤は、口腔内崩壊時の食感も改善されていることが明らかとなった。
すなわち、本発明の実施で得られる速崩壊性錠剤は、錠剤として適切な硬度を有しており、口腔内で速やかに崩壊し、好ましい風味を付与されているものとなる。
As shown in Table 7 and FIG. 3, all tablets had a disintegration time of 1 minute or less, and the disintegration time in the oral cavity was dramatically shortened by granulating and sizing the powdered fragrance. Moreover, the disintegration time in the oral cavity could be shortened within 40 seconds by setting the particle size of the powdered fragrance to 300 μm or more. Furthermore, when the particle size of the powdered fragrance was 500 μm or more, the oral disintegration time could be shortened to about 30 seconds. In addition, the texture in the oral cavity was favorably evaluated because the discomfort of the texture disappeared when the particle size was 500 μm.
From the above test results, in order to suppress the disintegration delay due to the essential oil contained in the powder fragrance, the particle size of the powder fragrance may be adjusted to 300 μm or more, and if the particle size is adjusted to 500 μm or more, the functional surface will be improved Became clear.
Moreover, it became clear that the formulation prepared using such a powder fragrance | flavor has also improved the food texture at the time of an oral disintegration.
That is, the rapidly disintegrating tablet obtained by carrying out the present invention has an appropriate hardness as a tablet, disintegrates rapidly in the oral cavity, and has a preferred flavor.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013057695A JP6092672B2 (en) | 2013-03-21 | 2013-03-21 | Orally rapidly disintegrating tablets |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013057695A JP6092672B2 (en) | 2013-03-21 | 2013-03-21 | Orally rapidly disintegrating tablets |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014181221A JP2014181221A (en) | 2014-09-29 |
JP6092672B2 true JP6092672B2 (en) | 2017-03-08 |
Family
ID=51700265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013057695A Active JP6092672B2 (en) | 2013-03-21 | 2013-03-21 | Orally rapidly disintegrating tablets |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6092672B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6334482B2 (en) * | 2015-08-28 | 2018-05-30 | 中野Bc株式会社 | Solid agent and production method thereof |
JP7334025B2 (en) * | 2017-06-30 | 2023-08-28 | 小林製薬株式会社 | Oral composition in which glucosamine is coated with a calcium compound |
MX2020007321A (en) * | 2017-12-14 | 2020-08-24 | Firmenich & Cie | Process for releasing an active ingredient. |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2060736T3 (en) * | 1989-01-12 | 1994-12-01 | Bayer Ag | EFFERVESCENT ANALGESIC ANTI-ACID COMPOSITION WITH A REDUCED SODIUM CONTENT. |
DE19814256A1 (en) * | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Solid, fast-breaking cetirizine formulations |
JP4273277B2 (en) * | 1999-06-30 | 2009-06-03 | 大塚製薬株式会社 | Oligosaccharide supplement composition |
JP2002308747A (en) * | 2001-04-10 | 2002-10-23 | Lion Corp | Foamable solid composition for oral cavity |
JP4566620B2 (en) * | 2004-05-14 | 2010-10-20 | 花王株式会社 | Granulated material |
JP4965130B2 (en) * | 2006-01-26 | 2012-07-04 | 日本臓器製薬株式会社 | Dry type quick-disintegrating tablet |
JP5945191B2 (en) * | 2012-08-09 | 2016-07-05 | 株式会社ファンケル | Intraoral quick disintegrating tablet |
-
2013
- 2013-03-21 JP JP2013057695A patent/JP6092672B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2014181221A (en) | 2014-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000078292A1 (en) | Quickly disintegrating solid preparations | |
JP6086798B2 (en) | Tablet manufacturing method | |
JP5342028B2 (en) | Orally disintegrating tablets | |
JP6133445B2 (en) | Oral rapidly disintegrating composition for solid preparation | |
JP6153867B2 (en) | Orally disintegrating tablets | |
JP2006070046A (en) | Quick disintegrable solid preparation | |
JP2007197357A (en) | Dry directly tableted quick-disintegrating tablet | |
JP5945191B2 (en) | Intraoral quick disintegrating tablet | |
WO2005004923A1 (en) | Tablet and process for producing the same | |
JP6092672B2 (en) | Orally rapidly disintegrating tablets | |
JP2003034655A (en) | Fast degradable solid tablet | |
JPWO2012001977A1 (en) | Disintegrating composition and easily disintegrating compression molding | |
JP2010241760A (en) | Tablet quickly disintegrable in oral cavity that has unpleasant taste reduced, and method for preparing the same | |
JP6262490B2 (en) | Intraoral rapidly disintegrating tablet composition | |
JP5902677B2 (en) | Orally disintegrating tablets of erythritol and isomalt | |
JPWO2008081774A1 (en) | Orally disintegrating tablets and bitterness-suppressing preparations containing risperidone | |
JP6438547B2 (en) | Intraoral rapidly disintegrating tablet composition | |
JP7360460B2 (en) | Orally disintegrating tablet and its manufacturing method | |
JP2017125002A (en) | Bitter taste suppressing method using mannitol powders | |
KR102290312B1 (en) | Composition for tablet and preparing method thereof | |
JP6700083B2 (en) | Orally fast disintegrating tablets | |
CN107921045B (en) | Zolpidem composition and preparation method thereof | |
TWI406679B (en) | Oral disintegrating tablet containing a high dosage of active ingredients | |
JP4804737B2 (en) | Calcium-containing rapidly disintegrating solid preparation | |
CN113679687A (en) | Composite drug release composition, orally disintegrating tablet composition, orally disintegrating preparation and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151029 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160920 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161102 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170207 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170209 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6092672 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |